Affimer-Based Europium Chelates Allow Sensitive Optical Biosensing in a Range of Human Disease Biomarkers.

Eiman Al-Enezi, Alexandre Vakurov, Amy Eades, Mingyu Ding, Gin Jose, Sikha Saha, Paul Millner

Abstract read

In one paragraph

Article in Sensors (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

Investigation of Peptides for Molecular Recognition of C-Reactive Protein-Theoretical and Experimental Studies.Analytical chemistry · 2023
Article
Recent Progress in Biosensors for Detection of Tumor Biomarkers.Molecules (Basel, Switzerland) · 2022
Review
Diagnoses Based on C-Reactive Protein Point-of-Care Tests.Biosensors · 2022
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Eiman Al-EneziBionanotechnology Group, School of Biomedical Science, University of Leeds, Leeds LS2 9JT, UK.

Alexandre VakurovBionanotechnology Group, School of Biomedical Science, University of Leeds, Leeds LS2 9JT, UK.ORCID 0000-0001-6654-4287

Amy EadesBionanotechnology Group, School of Biomedical Science, University of Leeds, Leeds LS2 9JT, UK.

Mingyu DingBionanotechnology Group, School of Biomedical Science, University of Leeds, Leeds LS2 9JT, UK.

Gin JoseSchool of Chemical and Process Engineering, University of Leeds, Leeds LS2 9JT, UK.ORCID 0000-0001-9856-6755

Sikha SahaSchool of Medicine, University of Leeds, Leeds LS2 9JT, UK.

Paul MillnerBionanotechnology Group, School of Biomedical Science, University of Leeds, Leeds LS2 9JT, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The protein biomarker measurement has been well-established using ELISA (enzyme-linked immunosorbent assay), which offers good sensitivity and specificity, but remains slow and expensive. Certain clinical conditions, where rapid measurement or immediate confirmation of a biomarker is paramount for treatment, necessitate more rapid analysis. Biosensors offer the prospect of reagent-less, processing-free measurements at the patient's bedside. Here, we report a platform for biosensing based on chelated Eu

Indexed as

Biosensing TechniquesEuropiumBiomarkersChelating AgentsEnzyme-Linked Immunosorbent AssayHumansBiomarkersChelating AgentsEuropiumAffimerbiomarkersbiosensoreuropium chelateslanthanide

Identifiers

PMID33513673

DOI10.3390/s21030831

PMCPMC7865513

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.